1 сент. 2024 г. · Finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo.

14 мая 2024 г. · The FINEARTS-HF trial is designed to evaluate the long-term efficacy and safety of the selective non-steroidal MRA finerenone among patients with HF with ...

24 окт. 2024 г. · The FINEARTS-HF trial showed that in patients with symptomatic HF with preserved or mildly reduced LVEF, finerenone resulted in a lower composite rate of ...

29 сент. 2024 г. · This study examined the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone in relation to the ...

5 авг. 2024 г. · Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to ...

5 авг. 2024 г. · Finerenone (Kerendia), a nonsteroidal, selective mineralocorticoid receptor antagonist (nsMRA) can reduce the composite of cardiovascular death and total heart ...

The objective of this study is to demonstrate the superiority of finerenone to placebo in reducing the rate of cardiovascular death and heart failure events.

29 сент. 2024 г. · In the FINEARTS-HF, the nonsteroidal MRA finerenone reduced the risk of cardiovascular death and total worsening heart failure events in ...

Информация об этой странице недоступна. ·

2 сент. 2024 г. · Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality ...